HF
CBAY

Hoxton Financial’s Cymabay Therapeutics CBAY Stock Holding History

Hoxton Financial’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$35K Hold
25,920
– – 0.02% 169
2015
Q4 		$44K Buy
+25,920
New +$42.3K 0.02% 137

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Hoxton Financial's CBAY Position: Q1 2016 in Review

Hoxton Financial held its Cymabay Therapeutics (CBAY) position steady in Q1 2016 at 25,920 shares worth $35K. The position accounts for 0.02% of the portfolio, ranked #169.

Hoxton Financial first reported a position in CBAY in Q4 2015 and has held it in 2 quarters since. The position peaked at $44K in Q4 2015. 30 funds tracked by Wall St. Rank hold CBAY as of Q1 2016.

  • Hoxton Financial held 25,920 shares of Cymabay Therapeutics worth $35K as of Q1 2016.
  • Hoxton Financial left its Cymabay Therapeutics share count unchanged in Q1 2016.
  • Cymabay Therapeutics made up 0.02% of Hoxton Financial's portfolio in Q1 2016, its #169 holding.
  • Hoxton Financial first reported a position in Cymabay Therapeutics in Q4 2015 and has held it in 2 quarters since.
  • Hoxton Financial's Cymabay Therapeutics position peaked at $44K in Q4 2015.
  • 30 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2016.

Based on Hoxton Financial's 13F filing for Q1 2016, filed 29 Apr 2016.